David Araujo
Overview
Explore the profile of David Araujo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
655
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Magalhaes Ferreira P, Ferreira J, Freitas C, Sousa C, Araujo D, Novais Bastos H, et al.
Monaldi Arch Chest Dis
. 2025 Feb;
PMID: 39992305
Venous thromboembolism (VTE) is highly prevalent in cancer patients. While its actual incidence remains disparate among studies, specific subpopulations, such as lung cancer patients, might be at an increased risk....
2.
Martins B, Guimaraes S, Araujo D
Arch Bronconeumol
. 2024 Oct;
61(1):52-54.
PMID: 39438202
No abstract available.
3.
Elkady A, Elliott C, Fetco D, Araujo D, Karimaghaloo Z, Ganzetti M, et al.
J Magn Reson Imaging
. 2024 Sep;
61(4):1812-1828.
PMID: 39239775
Background: Multiple sclerosis (MS) paramagnetic rim lesions (PRLs) are markers of chronic active biology and exhibit complex iron and myelin changes that may complicate quantification when using conventional MRI approaches....
4.
Casco N, Jorge A, Palmero D, Alffenaar J, Fox G, Ezz W, et al.
Eur Respir J
. 2023 Oct;
62(5).
PMID: 37827576
Background: Longitudinal cohort data of patients with tuberculosis (TB) and coronavirus disease 2019 (COVID-19) are lacking. In our global study, we describe long-term outcomes of patients affected by TB and...
5.
Elliott C, Rudko D, Arnold D, Fetco D, Elkady A, Araujo D, et al.
Mult Scler
. 2023 Apr;
29(6):680-690.
PMID: 37036134
Background: Paramagnetic rim lesions (PRLs) and slowly expanding lesions (SELs) have been posited as markers of chronic active lesions (CALs). Objective: To assess the lesion-level concordance of PRLs and SELs...
6.
7.
Coelho D, Santos V, Araujo D, Novais Bastos H, Magalhaes A, Hespanhol V, et al.
Front Mol Biosci
. 2021 Aug;
8:639676.
PMID: 34368223
Background: Cancer patients appear to be at a higher risk of complications from coronavirus disease 2019 (COVID-19). Specific data related to lung cancer (LC) patient management, active treatment, and/or recent...
8.
Freitas C, Serino M, Araujo D, Pinto T, van Zeller M, Goncalves M, et al.
Clin Respir J
. 2021 Jul;
15(10):1130-1138.
PMID: 34224645
Introduction: Although long-term home non-invasive ventilation (H-NIV) has been used among chronic hypercapnic COPD patients, its clinical benefit is still on debate. We aim to assess the impact of H-NIV...
9.
Fernandes M, Sousa C, Jacob M, Almeida L, Santos V, Araujo D, et al.
Front Oncol
. 2021 May;
11:602924.
PMID: 34026599
Osimertinib efficacy in pre-treated patients with epidermal growth factor receptor (EGFR) T790M-mutated non-small cell lung cancer (NSCLC) has been demonstrated in clinical trials, but real-world data, particularly regarding resistance profile,...
10.
Freitas C, Jacob M, Tavares N, Cruz-Martins N, Souto-Moura C, Araujo D, et al.
Anticancer Drugs
. 2021 Mar;
32(5):567-574.
PMID: 33661189
Immune checkpoint inhibitors were approved for advanced nonsmall cell lung cancer (NSCLC) treatment. Despite improved survival, not all patients benefit from these agents. Here, the prognostic impact of pretreatment modified...